Peter T. W. Cheng
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine(CN)Xinjiang Institute of Engineering(CN)Bristol-Myers Squibb (Sweden)(SE)Wuhan National Laboratory for Optoelectronics(CN)
Publications by Year
Research Areas
Peroxisome Proliferator-Activated Receptors, Catalytic C–H Functionalization Methods, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Catalytic Cross-Coupling Reactions
Most-Cited Works
- → Ligand-accelerated non-directed C–H functionalization of arenes(2017)420 cited
- → A tautomeric ligand enables directed C‒H hydroxylation with molecular oxygen(2021)165 cited
- → Ligand‐Promoted Borylation of C(sp3)H Bonds with Palladium(II) Catalysts(2015)145 cited
- → Overcoming Limitations in Decarboxylative Arylation via Ag–Ni Electrocatalysis(2022)132 cited
- → Catalytic Ring Expansions of Cyclic Alcohols Enabled by Proton-Coupled Electron Transfer(2019)112 cited
- → Nickel-Catalyzed 1,2-Carboamination of Alkenyl Alcohols(2021)111 cited
- → Design and Synthesis of -[(4-Methoxyphenoxy)carbonyl]--[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities